Abstract
Tumor-infiltrating lymphocytes as a predictive biomarker of cutaneous immune-related adverse events after immune checkpoint blockade in patients with advanced melanoma
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have